| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7122566 | KING PHARMS | Metaxalone products, method of manufacture, and method of use |
Feb, 2026
(2 years from now) | |
Skelaxin is owned by King Pharms.
Skelaxin contains Metaxalone.
Skelaxin has a total of 1 drug patent out of which 0 drug patents have expired.
Skelaxin was authorised for market use on 30 August, 2002.
Skelaxin is available in tablet;oral dosage forms.
Skelaxin can be used as treatment of musculoskeletal conditions.
The generics of Skelaxin are possible to be released after 06 February, 2026.
Drugs and Companies using METAXALONE ingredient
Market Authorisation Date: 30 August, 2002
Treatment: Treatment of musculoskeletal conditions
Dosage: TABLET;ORAL
How can I launch a generic of SKELAXIN before it's drug patent expiration?
More Information on Dosage
SKELAXIN family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic